Orexo Ab operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Orexo Ab with three other
pharmaceutical manufacturers in Europe:
Eco Animal Health Group Plc
of the United Kingdom
sales of £61.42 million [US$79.67 million]
COSMO Pharmaceuticals SA
(67.24 million Euro [US$75.89 million]
based in Romania
(336.90 million Romanian Leu [US$81.64 million]
During the year ended December of 2017, sales at
Orexo Ab were SEK 643.70 million (US$71.10 million).
decrease of 8.8%
versus 2016, when the company's sales were SEK 705.90 million.
Contributing to the drop in overall sales was the 91.5% decline
in Zubsolv Non Us Upfront Payment, from SEK 65.90 million to SEK 5.60 million.
There were also decreases in sales in
Other Revenue/ R&d (down 46.6% to SEK 21.80 million)
However, these declines were partially offset by the increase in sales of
Zubsolv (up 0.8% to SEK 485.80 million)
Royalty - Abstral (up 12.7% to SEK 113.20 million)
Royalty - Edluar (up 16.9% to SEK 17.30 million)